(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The Tradition of Stone: A Gander at Notable Structures Through the Ages- Embrace Effortlessness: Moderation and Cleaning up Tips
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- Becoming amazing at Systems administration: Individual and Expert Tips
- Russia confirms 16 Cameroonian soldiers killed in Ukraine war
- Mating injuries may lead scientists to identify dinosaurs’ sex
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- Remain Cool and Solid: Top Summer Food sources for 2024
- 'People We Meet on Vacation' is the 1st of many Emily Henry adaptations: What other books turned movies to look forward to
